Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
2007-01-23
2007-01-23
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
C424S130100, C424S155100
Reexamination Certificate
active
10651453
ABSTRACT:
The present invention relates to monoclonal antibody H11 and antigen binding fragments that specifically bind to the antigen recognized by H11, the C-antigen. The C-antigen is found specifically on neoplastic cells and not on normal cells. Also disclosed are polynucleotide and polypeptide derivatives based on H11, including single chain V region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the H11 antibody is effective in diagnosing, localizing, and/or treating neoplasias. The invention further provides methods for treating a neoplastic disease, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell lung carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treated with a composition of this invention in hopes of reducing the risk of recurrence. Patients may also be treated concurrently with the antibodies and traditional anti-neoplastic agents.
REFERENCES:
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3939350 (1976-02-01), Kronick et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4275149 (1981-06-01), Litman et al.
patent: 4277437 (1981-07-01), Maggio
patent: 4366241 (1982-12-01), Tom et al.
patent: 4618477 (1986-10-01), Babu et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4754065 (1988-06-01), Levenson et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4983586 (1991-01-01), Bodor
patent: 5002935 (1991-03-01), Bodor
patent: 5017566 (1991-05-01), Bodor
patent: 5153179 (1992-10-01), Eibl
patent: 5270202 (1993-12-01), Raychaudhuri
patent: 5474755 (1995-12-01), Hanna, Jr. et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 6146631 (2000-11-01), Better et al.
patent: 6207153 (2001-03-01), Dan et al.
patent: 0 329 400 (1989-08-01), None
patent: 0 699 755 (1996-03-01), None
patent: WO 91/04014 (1991-04-01), None
patent: WO-92/20799 (1992-11-01), None
patent: WO 93/07286 (1993-04-01), None
patent: WO 95/35374 (1995-12-01), None
patent: WO-97/44461 (1997-11-01), None
patent: WO-97/44461 (1997-11-01), None
MSNBC News Services, “Mixed results on new cancer drug”, Nov. 2000.
Jain, “Barriers to drug delivery in solid tumors”, Sci. Am. 171 (1), 58-65, 1994.
Gura, “Systems for identifying new drugs are often faulty”, Science 278 (5340), 1041-1042, 1997.
Freshney, Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, pp. 3-4.
Dermer, Bio/Technology, 1994, 12:320.
Rudikoff et al., Proc. Natl. Acad. Sci. USA, 1982, vol. 79, 1979-1983.
Gura, T. (Nov. 7, 1997). “Systems for Identifying New Drugs Are Often Faulty,”Science278:1041-1042.
International Search Report mailed on Mar. 17, 1998 for PCT Patent Application No. PCT/US97/08962 filed on May 22, 1997, 5 pages.
Loparco, D. (May 26, 1999). “Novapham Biotech Inc. Announces Evidence of Anti-Cancer Activity Utilizing Fully Human Antibodies in Pre-Clinical Animal Studies,”Novapharm Biotech, 3 pages (Press Release).
Loparco, D. (Oct. 7, 1999). “Anti-Cancer Treatment Shows Potential to Significantly Reduce Spread of Breast Cancer,”Novapharm Biotech2 pages (Press Release).
Maiti, P. K. et al. (1995). “Development and Characterization of Pancarcinoma Specific Human Monoclonal Anitbody H11 (NOVOMAb-G2),”Biotechnol. Internationalpp. 85-93.
McKnight, M. et al. (Mar. 1993). “Monopham-C, A Human Ant-icancer MAb: Generation. Production and Immunological Properties,”Proceedings of the American Association for Cancer Researchvol. 34, p. 223, Abstract No. 1330.
Novapharm Biotech Inc., (Jan. 2000). Corporate Profile, 2 pages.
Padian, E. A. (1994). “Anatomy of the Antibody Molecule,”Molecular Immunol. 31(3):169-217.
Pastan, I. H. et al. (Mar. 1995). “Intrathecal Administration of Single-Chain Immunotoxin, LMB-7 [B3(Fv)-PE38], Produces Cures of Carcinomatous Meningitis in a Rat Model,”Proc. Natl. Acad. Sci. USA92:2765-2769.
Rieger, R. et al. (1976).Glossary of Genetics and Cytogenetics: Classical and Molecular. Springer-Verlag: Berlin, Heidlberg, New York, pp. 17-19.
Weiner, L. M. (Aug. 1999). “An Overview of Monoclonal Antibody Therapy of Cancer,”Seminars in Oncology26(4) Suppl 12:41-50.
Westwood, O. M. R. et al., eds. (2000). “Protein Sequence Analysis” Chapter 2.2In Epitope Mapping: A Practical Approach. Oxford University Press. pp. 5-6.
Alonso, “Human—human monoclonal antibody directed against tumor surface antigen in the treatment of human malignancy”,Am. J. Clin. Oncol. (1991) 14:463-471.
Baba et al., “Intracartoid infusion of leukotriene C4selectively increases blood-brain barrier permeability after focal ischemia in rats”J. Cerebral Blood Flow Metab. (1991) 11:638-643.
Ballou et al., “Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies”Cancer Immunol. Immunother. (1995) 41:257-263.
Barbas, “Synthetic human antibodies”Nature Med. (1995) 1:837-839.
Bickel et al., “Pharmacologic effectsin vivoin brain by vector-mediated peptide drug delivery”,Proc. Natl. Acad. Sci. USA(1993) 90:2618-2622.
Bird et al., “Single-chain antigen-binding proteins”Science(1988) 242:423-426.
Boone et al., “Isolation of plasma membrane fragments from hela cells”J. Cell. Biol. (1969) 41:378-392.
Borup-Christensen et al., “Human—human hybridomas generated with lymphocytes from patients with colorectal cancer”Cancer Detect. Prevent. Suppl. (1987) 1:207-215.
Brown et al., “Chimeric parvovirus B19 capsids for the presentation of foreign epitopes”Virol. (1994) 198:477-488.
Buck et al., “Production of Human Monoclonal Antibodies”Monoclonal Antibodies and Cell Lines, 1984, Plenum Press, New York, Chapter 11, pp. 275-308.
Carter et al., “Isolation and partial characterization of ‘galactoprotein a ’ (LETS) and ‘galactoprotein b’ from hamster embryo fibroblasts”Biochem. Biophys. Res. Commun. (1977) 76:299-308.
Chatal et al., “Clinical prospective study with radioiodinated monoclonal antibodies directed against colorectal cancer”Monoclonal Antibodies for Cancer Detection and Therapy(1985) Baldwin et al., eds., Academic Press, Chapter 8, pp. 159-180.
Chaudhuri et al., “Human monoclonal antibody developed against ovarian cell surface antigen” Cancer (1994) 73:1098-1104.
Cheresh et al., “Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis”Proc. Natl. Acad. Sci USA(1985) 82:5155-5159.
Cheresh et al., “Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis”Cancer Res. (1986) 46:5112-5118.
Coclett et al., “High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification”Bio/Technology(1990) 8:662-667.
Cohen, “Cancer vaccines get a shot in the arm”Science(1993) 262:841-843.
Colditz, “Epidemiology of breast cancer”Cancer(1993) 71:1480-1489.
Cote et al., “Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens”Proc. Natl. Acad. Sci. USA(1986) 83:2959-2963.
Dermer et al.,Bio/Technology(1994) Mar.; 12:320.
Diener et al., “Specific immunosuppression by immunotoxins containing daunomycin”Science(1986) 231:148-150.
Ditzel et al., “Immunoscintigraphy of colon cancers with the human monoclonal antibody COU-1”Cancer(1994) 73:858-863.
Douillard et al., “Monoclonal antibodies specific immunotherapy of gastrointestinal tumors”Hybridoma(1986) 5:Supp. 1:S139-S149.
Dan Michael D.
Grad, legal representative Carol
Maiti Pradip K.
Bereskin & Parr
Gravelle Micheline
Helms Larry R.
Sang Hong
Viventia Biotech Inc.
LandOfFree
Antigen binding fragments that specifically detect cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigen binding fragments that specifically detect cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen binding fragments that specifically detect cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3793447